If I'd invested $1,000 in CSL shares 24 years ago, here's how much I'd have now!

While some companies have lost value or even collapsed since listing, you might be surprised how many ASX 200 shares have rocketed over the long term.

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares first listed on the ASX way back on 8 June 1994.

The S&P/ASX 200 Index biotechnology company floated for $2.30 per share. But once we take share buybacks into account, the adjusted entry price works out to around 76 cents per share.

We won't go back quite that far.

But here's how much I'd have now if I'd invested $1,000 in CSL shares 24 years ago.

Invest in CSL shares like it's 1999

Investing with perfect hindsight is a wonderful thing.

While some companies have lost value or even collapsed since listing, you might be surprised how many ASX 200 shares have rocketed over the long term.

CSL shares certainly count among the winners.

Back on 16 April 1999, CSL closed the day trading for $4.23 per share.

That means I could have bought 236 shares with my $1,000 and had enough left over for a cup of 1999-priced coffee.

At the time of writing, CSL is trading for $304.31 per share.

If I opted to sell those 236 shares today they'd get me a whopping $71,817 and change.

In other words, the stock would have seen me gain 7,081% on my initial investment over 24 years, from share price appreciation alone.

Don't forget the dividends!

But let's not forget that CSL shares also have a lengthy track record of delivering dividends.

According to my calculations, the biotech company has paid out approximately $28 per share in dividends since April 1999. That's more than six times what I would have paid for those shares in 1999.

Assuming I didn't reinvest those dividends but simply tucked the cash under my mattress for a rainy day, I'd have earned some $6,608 in passive income from my 236 shares.

Adding that in, my total gains on that $1,000 investment in 1999 have leapt to an eye-popping 7,742%.

Granted, inflation over that period will have cut those gains roughly in half in real terms.

But still, try getting that kind of yield from your bank!

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »